SUWANEE, GA, Dec. 27, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (OTCQB: SNWV) an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, announces the last installment of its blog for the year 2018, “SHOCK THIS” on its website www.sanuwave.com. As with previous installments, this interview was led by SANUWAVE's Chief Science and Technology Officer, Dr. Iulian Cioanta, titled "Seasoned Executive Shares his Views on Shockwave Technology, its Past, Present, and Future. – A. Michael Stolarski, the Owner, President and Chief Executive Officer of Premier Shockwave, Inc. and Premier Shockwave Wound Care, Inc."
In 2018, our focus with the blog continues to be on opinions expressed in interviews with pioneers and influential personalities who’ve added significant contributions towards advancing wound care and the use of shockwave technology. Therefore, in this new blog, SANUWAVE presents an interview with Shri Parikh, who joined SANUWAVE six months ago, as the President of Healthcare Division. The interview emphasizes Shri’s personality, background, ideas, and his vision on the commercialization of dermaPACE® System for diabetic foot ulcers (DFUs), in capitalizing on existing shockwave systems offered by the company and in the same time advancing SANUWAVE’s shockwave technology into new medical verticals.
The goal of the blog is to allow a medium to help educate customers, patients, partners, and the public about the various initiatives under way at SANUWAVE. The blog will also accept posts and comments (approved by SANUWAVE), which the Company views as valuable to the SANUWAVE community. This is expected to be a constructive forum for users from around the globe. By having a central location, SHOCK THIS, the Company can centralize information that will be useful and entertaining to the SANUWAVE community. Members of the SANUWAVE community are encouraged to interact and reach out with thoughts and ideas, which will positively impact the SANUWAVE community. SANUWAVE Health, Inc. reserves the right to edit or exclude comments it deems not positively impacting the experience or is not appropriate from legal and regulatory perspectives.
About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, Australia and New Zealand. In the U.S., dermaPACE®, is currently under the FDA’s Premarket Approval (PMA) review process for the treatment of diabetic foot ulcers. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron®, Evotron® and orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE’s shock wave technology for non-medical uses, including energy, water, food and industrial markets.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
For additional information about the Company, visit www.sanuwave.com